Literature DB >> 12162725

Complementary actions of VEGF and angiopoietin-1 on blood vessel growth and leakage.

Gavin Thurston1.   

Abstract

Vascular endothelial growth factor (VEGF) and Angiopoietins are families of vascular-specific growth factors that regulate blood vessel growth, maturation and function. To learn more about the effects of these factors in vivo, we have overexpressed VEGF-A or Angiopoietin-1 (Ang1) in two systems in mice, and examined the effects on blood vessel growth and function. In one set of studies, VEGF, Ang1, or both factors, were transgenically overexpressed in the skin under the keratin-14 (K14) promoter. The skin of mice overexpressing VEGF (K14-VEGF) had numerous tortuous, capillary-sized vessels which were leaky to the plasma tracer Evans blue under baseline conditions. In contrast, the skin of mice overexpressing Ang1 (K14-Ang1) had enlarged dermal vessels without a significant increase in vessel number. These enlarged vessels were less leaky than those of wild-type mice in response to inflammatory stimuli. In double transgenic mice overexpressing VEGF and Ang1, the size and number of skin vessels were both increased; however, the vessels were not leaky. In a second set of studies, VEGF or Ang1 was systemically delivered using an adenoviral approach. Intravenous injection of adenovirus encoding VEGF (Adeno-VEGF) resulted in widespread tissue oedema within 1-2 days after administration, whereas injection of Adeno-Ang1 resulted in the skin vessels becoming less leaky in response to topical inflammatory stimuli or local injection of VEGF. The decreased leakage was not accompanied by morphological changes. Thus, overexpressing VEGF appears to promote growth of new vessels accompanied by plasma leakage, whereas overexpressing Ang1 promotes the enlargement of existing vessels and a resistance to leakage. Further understanding of the interrelationship of these factors during normal development could lead to their application in the treatment of ischaemic diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12162725      PMCID: PMC1570748          DOI: 10.1046/j.1469-7580.2002.00061.x

Source DB:  PubMed          Journal:  J Anat        ISSN: 0021-8782            Impact factor:   2.610


  25 in total

Review 1.  Vascular-specific growth factors and blood vessel formation.

Authors:  G D Yancopoulos; S Davis; N W Gale; J S Rudge; S J Wiegand; J Holash
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

2.  Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression.

Authors:  A I Michou; L Santoro; M Christ; V Julliard; A Pavirani; M Mehtali
Journal:  Gene Ther       Date:  1997-05       Impact factor: 5.250

3.  Purification and cloning of vascular endothelial growth factor secreted by pituitary folliculostellate cells.

Authors:  N Ferrara; D W Leung; G Cachianes; J Winer; W J Henzel
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

Review 4.  Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation.

Authors:  H F Dvorak; J A Nagy; B Berse; L F Brown; K T Yeo; T K Yeo; A M Dvorak; L van de Water; T M Sioussat; D R Senger
Journal:  Ann N Y Acad Sci       Date:  1992-12-04       Impact factor: 5.691

5.  Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1.

Authors:  G Thurston; C Suri; K Smith; J McClain; T N Sato; G D Yancopoulos; D M McDonald
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

6.  VEGF gene delivery to myocardium: deleterious effects of unregulated expression.

Authors:  R J Lee; M L Springer; W E Blanco-Bose; R Shaw; P C Ursell; H M Blau
Journal:  Circulation       Date:  2000-08-22       Impact factor: 29.690

7.  Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia.

Authors:  I Baumgartner; A Pieczek; O Manor; R Blair; M Kearney; K Walsh; J M Isner
Journal:  Circulation       Date:  1998-03-31       Impact factor: 29.690

8.  VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development.

Authors:  F Larcher; R Murillas; M Bolontrade; C J Conti; J L Jorcano
Journal:  Oncogene       Date:  1998-07-23       Impact factor: 9.867

9.  Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo.

Authors:  D J Dumont; G Gradwohl; G H Fong; M C Puri; M Gertsenstein; A Auerbach; M L Breitman
Journal:  Genes Dev       Date:  1994-08-15       Impact factor: 11.361

10.  Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice.

Authors:  M Detmar; L F Brown; M P Schön; B M Elicker; P Velasco; L Richard; D Fukumura; W Monsky; K P Claffey; R K Jain
Journal:  J Invest Dermatol       Date:  1998-07       Impact factor: 8.551

View more
  43 in total

Review 1.  The phenotype of the human materno-fetal endothelial barrier: molecular occupancy of paracellular junctions dictate permeability and angiogenic plasticity.

Authors:  Lopa Leach
Journal:  J Anat       Date:  2002-06       Impact factor: 2.610

2.  Intussusceptive microvascular growth in human glioma.

Authors:  Beatrice Nico; Enrico Crivellato; Diego Guidolin; Tiziana Annese; Vito Longo; Nicoletta Finato; Angelo Vacca; Domenico Ribatti
Journal:  Clin Exp Med       Date:  2009-10-31       Impact factor: 3.984

3.  Synthetic two-way communication between mammalian cells.

Authors:  William Bacchus; Moritz Lang; Marie Daoud El-Baba; Wilfried Weber; Jörg Stelling; Martin Fussenegger
Journal:  Nat Biotechnol       Date:  2012-09-16       Impact factor: 54.908

Review 4.  Angiogenesis in the human corpus luteum.

Authors:  Norihiro Sugino; Aki Matsuoka; Ken Taniguchi; Hiroshi Tamura
Journal:  Reprod Med Biol       Date:  2008-04-17

5.  Adipose-derived stromal cells overexpressing vascular endothelial growth factor accelerate mouse excisional wound healing.

Authors:  Allison Nauta; Catharina Seidel; Lorenzo Deveza; Daniel Montoro; Monica Grova; Sae Hee Ko; Jeong Hyun; Geoffrey C Gurtner; Michael T Longaker; Fan Yang
Journal:  Mol Ther       Date:  2012-11-20       Impact factor: 11.454

6.  Transgenic overexpression of keratinocyte-specific VEGF and Ang1 in combination promotes wound healing under nondiabetic but not diabetic conditions.

Authors:  Candace M Loyd; Doina Diaconu; Wen Fu; Gregory N Adams; Erin Brandt; Dorothy A Knutsen; Julie A Wolfram; Thomas S McCormick; Nicole L Ward
Journal:  Int J Clin Exp Pathol       Date:  2012-01-01

7.  Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.

Authors:  Analia Rodríguez Garzotto; C Vanesa Díaz-García; Alba Agudo-López; Elena Prieto García; Santiago Ponce; José A López-Martín; Luis Paz-Ares; Lara Iglesias; M Teresa Agulló-Ortuño
Journal:  Med Oncol       Date:  2016-08-27       Impact factor: 3.064

8.  Vascular endothelial cadherin and beta-catenin in human fetoplacental vessels of pregnancies complicated by Type 1 diabetes: associations with angiogenesis and perturbed barrier function.

Authors:  L Leach; C Gray; S Staton; M O Babawale; A Gruchy; C Foster; T M Mayhew; D K James
Journal:  Diabetologia       Date:  2004-04       Impact factor: 10.122

9.  Placental gene transfer: transgene screening in mice for trophic effects on the placenta.

Authors:  Anna B Katz; Sundeep G Keswani; Mounira Habli; Foong Y Lim; Philip W Zoltick; Paola Midrio; Elliot D Kozin; Meenhard Herlyn; Timothy M Crombleholme
Journal:  Am J Obstet Gynecol       Date:  2009-08-28       Impact factor: 8.661

10.  Coadministration of adenoviral vascular endothelial growth factor and angiopoietin-1 enhances vascularization and reduces ventricular remodeling in the infarcted myocardium of type 1 diabetic rats.

Authors:  Samson Mathews Samuel; Yuzo Akita; Debayon Paul; Mahesh Thirunavukkarasu; Lijun Zhan; Perumana R Sudhakaran; Chuanfu Li; Nilanjana Maulik
Journal:  Diabetes       Date:  2009-09-30       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.